Foster & Motley Inc. Sells 377 Shares of Halozyme Therapeutics, Inc. $HALO

Foster & Motley Inc. lessened its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.6% in the second quarter, HoldingsChannel.com reports. The fund owned 23,529 shares of the biopharmaceutical company’s stock after selling 377 shares during the period. Foster & Motley Inc.’s holdings in Halozyme Therapeutics were worth $1,224,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in HALO. Caisse DE Depot ET Placement DU Quebec lifted its holdings in shares of Halozyme Therapeutics by 154.5% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 910,169 shares of the biopharmaceutical company’s stock worth $58,078,000 after acquiring an additional 552,590 shares during the period. LSV Asset Management lifted its holdings in shares of Halozyme Therapeutics by 41.9% during the 1st quarter. LSV Asset Management now owns 895,191 shares of the biopharmaceutical company’s stock worth $57,122,000 after acquiring an additional 264,130 shares during the period. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Halozyme Therapeutics by 27.3% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,130,019 shares of the biopharmaceutical company’s stock worth $72,107,000 after acquiring an additional 242,167 shares during the period. MetLife Investment Management LLC lifted its holdings in shares of Halozyme Therapeutics by 136.6% during the 1st quarter. MetLife Investment Management LLC now owns 343,741 shares of the biopharmaceutical company’s stock worth $21,934,000 after acquiring an additional 198,476 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Halozyme Therapeutics during the 1st quarter worth approximately $11,636,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 0.2%

Shares of NASDAQ HALO opened at $67.03 on Friday. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $79.50. The firm has a 50 day moving average price of $71.56 and a two-hundred day moving average price of $62.09. The stock has a market cap of $7.84 billion, a P/E ratio of 15.34, a price-to-earnings-growth ratio of 0.36 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The firm had revenue of $325.72 million during the quarter, compared to analysts’ expectations of $282.66 million. During the same period in the prior year, the company posted $0.91 EPS. The company’s revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00. Following the sale, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at approximately $55,285,726.65. This represents a 2.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Nicole Labrosse sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the sale, the chief financial officer directly owned 24,306 shares in the company, valued at approximately $1,840,207.26. This represents a 45.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 108,227 shares of company stock worth $7,779,595. 2.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HALO. Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective for the company in a research report on Tuesday, October 14th. JPMorgan Chase & Co. upped their price objective on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday. Five research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $73.00.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.